Know Cancer

or
forgot password


Phase 3
18 Years
75 Years
Open (Enrolling)
Both
Carcinomas

Thank you

Trial Information


Inclusion Criteria:



1. Head and neck squamous cell carcinomas, stage I to IVb

2. First-line curative cancer therapy : surgery and/or brachytherapy and/or chemotherapy

3. HADS- T >11

4. Aged 18 to 75 yo, written consent required

5. OMS>2

Exclusion Criteria:

1. Palliative care

2. Previous head and neck cancer

3. Bipolar disorder or schizophrenia

4. Severe major depressive disorder (DSM-IV TR)

5. Expressed suicidal ideation

6. Severe untreated organic disorder, especially acute infectious disorder

7. ASAT/ALAT > 3N

8. Clearance of creatinin < 30 ml/mn

9. Hyponatremia

10. Antecedent of delirium tremens or acute alcohol withdrawal disorder

11. Antecedent of upper gastro-intestinal bleeding

12. Antecedent of toxicity or inefficacy of a previous treatment with escitalopram

13. Unauthorized treatments :- Antidepressant or antiepileptic (clonazepam authorized)-
Hypnotic except zolpidem - Anxiolytic except clonazepam, clorazepate or diazepam-
bupropion or varenicline

14. Pregnancy or lactation

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months

Outcome Time Frame:

3 months

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

TADDOR

NCT ID:

NCT00935675

Start Date:

Completion Date:

Related Keywords:

  • Carcinomas
  • Patients with head and neck squamous cell carcinomas
  • head and neck squamous cell carcinomas
  • Carcinoma
  • Head and Neck Neoplasms

Name

Location